Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Golden Cells is a proprietary allogeneic cell therapy developed by the Stem Cell Institute in Panama City, Panama. The treatment utilizes human umbilical cord tissue-derived mesenchymal stem cells (hUCT-MSCs) that are specifically selected from six unique cell lines identified through retrospective analysis of successful clinical outcomes. These cells are characterized by distinct molecular signatures that confer enhanced anti-inflammatory, immunomodulatory, and regenerative capabilities compared to standard mesenchymal stem cells. Golden Cells are used to treat a diverse range of conditions, including autism, multiple sclerosis, heart failure, and various autoimmune and orthopedic disorders, as well as for wellness and longevity applications. The cells are processed at the Medistem Panama laboratory and are typically administered via intravenous infusion or localized injection depending on the specific condition being treated.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Golden Cells.